Unity, Ascentage in cellular senescence deal

Anti-aging company Unity Biotechnology (San Francisco, Calif.) and Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) partnered to develop small molecules to treat age-related diseases by selectively inducing death of senescent cells.

Unity will gain access to Ascentage's library of small molecules that target programmed cell death. The companies also are forming a JV to develop and commercialize senolytic drugs in China. Unity declined to provide details. ...